Navigation Links
Questcor Reports Record Second Quarter Financial Results
Date:7/24/2014

ive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis."
  • Multiple Sclerosis (MS): "for the treatment of acute exacerbations of multiple sclerosis in adults. Clinical controlled trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease." When Acthar is used, it is typically prescribed as second line treatment for patients with MS exacerbations.
  • Infantile Spasms (IS): "as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age."
  • Non-GAAP Financial Measures The Company believes it is important to share non-GAAP financial measures with investors as these measures may better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, management believes investors' understanding of the Company's financial performance is enhanced as a result of the disclosure of these non-GAAP financial measures. Non-GAAP financial measures should not be viewed in isolation, or as a substitute for, or as superior to, reported GAAP financial measures. The reconciliation between GAAP and non-GAAP financial measures are provided with the financial tables included with this release.

    About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. For more information about Questcor, please visit
    '/>"/>

    SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

    Related medicine technology :

    1. Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
    2. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
    3. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
    4. Questcor Provides Donation In Support Of Childrens Hospital & Research Center Oakland
    5. Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways
    6. Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
    7. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
    8. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
    9. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
    10. Questcor Honored as an "Everyday Hero" by NephCure Foundation
    11. Questcor Adds G. Kelly Martin to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
    (Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
    (Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 Swedish ... Inc. today announced that the Committee for Medicinal Products ... (EMA) has adopted a positive opinion for the use ... adult men with Peyronie,s disease with a palpable plaque ... the start of therapy. The use of ...
    Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
    ... NOVATO, Calif., Aug. 13 BioMarin,Pharmaceutical Inc. (Nasdaq ... the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3,clinical trial ... of The Lancet.,The study suggests that treatment with ... in some phenylketonuria (PKU) patients.,Kuvan, an investigational oral ...
    ... Aug. 13 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ... oral presentation at the American Chemical Society National,Meeting ... 21, 2007,at 2:50 p.m. Eastern Time. The presentation, ... levels by enzyme inhibitors for the,potential treatment of ...
    Cached Medicine Technology:Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 2Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 3Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 4Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 5Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 2Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 3
    (Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
    (Date:12/25/2014)... Recently, BellasDress has launched its ... dresses. BellasDress has chosen their best-selling lace wedding dresses, ... the holiday season. , Now, BellasDress.com features popular ... here at discount prices. The business hopes everyone can ... , “All our elegant products are made ...
    (Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
    (Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
    (Date:12/25/2014)... 2014 (HealthDay News) -- The risk of burns from ... you need to be extra cautious, an expert says. ... a significant increase in patients coming in with burns," ... County Volunteer Firefighters Burn Center of Stony Brook University ... full of joy, but if not careful, could quickly ...
    Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2
    ... (RPI) has received a tentative approval from the US FDA ... for initial therapy or with other classes of anti-hypertenive agents. ... of heart failure and patients who do not respond to ... launch the product only in June 2002, when the original ...
    ... has approved a new method to treat women suffering excessive ... the tissue at fault. Millions of women suffer menorrhagia, benign ... than 20 tampons in a single day. Thousands of women ... try hormone treatment.// ,The other option is to ...
    ... levels that tend to be slightly elevated but still ... risk for suffering from heart disease. Blood pressure readings ... the first number in a blood pressure measurement, represents ... number, the diastolic value, represents the pressure when the ...
    ... man has received a self-contained artificial heart, but he ... University Hospital in Philadelphia, Pennsylvania, said. The medical team ... Surgeons have said previously that patients considered for the ... days to live. // ,"The operation went ...
    ... treating a resistant type of lymphoma, according to a ... many types of cancer cells, so it may be ... Fojo of the National Cancer Institute in Bethesda, Maryland, ... T-cell lymphoma, a cancer of the lymphatic system that ...
    ... help sort out whether people with aches and coughs have the ... Anthrax victims don't have runny noses. In general, the first symptoms ... wintertime viruses -- fever, ache, cough, no energy. // ... anthrax-killing antibiotics -- which do nothing for colds and flu -- ...
    Cached Medicine News:
    ... Lyphochek Elevated Immunosuppressant Control is a ... whole blood. This unique product is ideal ... very high Cyclosporine levels, such as C2 ... patients at two hours post-dose., ,Lyphochek Elevated ...
    Liquichek Hematology-16T Control is a hematology reference control used in monitoring determinations of blood cell values on TOA SYSMEX cell counters....
    NEW Liquichek Reticulocyte Control (A)is an assayed whole blood control for evaluating the precision of automated methods of reticulocyte counting....
    Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
    Medicine Products: